The ECHDC1 Knockout K-562 Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal population of K-562 cells in which the ECHDC1 gene has been disrupted. This format yields a heterogeneous pool of cells carrying loss-of-function mutations, enabling the study of gene function without the biases of clonal selection. It is ideal for acute deletion studies where maintaining population diversity is advantageous.
The host K-562 cell line, derived from a female patient in blast crisis of chronic myelogenous leukemia (CML), is characterized by the BCR-ABL fusion gene, conferring constitutive tyrosine kinase activity. K-562 is a well-established model for CML and erythropoiesis, capable of differentiating into erythroid and megakaryocytic lineages under appropriate stimuli, thus providing a versatile background for metabolic research.
ECHDC1 encodes ethylmalonyl-CoA decarboxylase, a mitochondrial matrix enzyme that catalyzes the decarboxylation of ethylmalonyl-CoA to propionyl-CoA. This step is integral to the catabolism of branched-chain amino acids (valine, leucine, isoleucine) and odd-chain fatty acids. The reaction operates downstream of the branched-chain alpha-keto acid dehydrogenase complex and isovaleryl-CoA dehydrogenase, and the product propionyl-CoA is further metabolized by methylmalonyl-CoA mutase to succinyl-CoA, linking amino acid and lipid breakdown to the TCA cycle.
In the context of BCR-ABL-positive K-562 cells, ECHDC1 knockout provides a model to dissect the intersection of oncogenic signaling and mitochondrial metabolism. Ablation of this enzyme may impair anaplerotic reactions critical for TCA cycle maintenance, potentially sensitizing leukemia cells to metabolic stress and revealing dependencies that could be targeted therapeutically.
This cell pool is suitable for a range of experimental approaches, including LC-MS-based metabolomic profiling to quantify ethylmalonyl-CoA, propionyl-CoA, and TCA cycle intermediates; Seahorse analysis to measure mitochondrial oxygen consumption; and cell viability assays under nutrient deprivation to assess metabolic vulnerabilities. It can be used for RT-qPCR screening of compensatory gene expression and for small-molecule inhibitor studies aimed at mitochondrial targets in leukemia. For further inquiries, please contact Ascent Research.
